Clinical Trials Browser

Phase 2 × OTHER × Adenocarcinoma, Mucinous × Clear all

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT05504252 2026-01-07

METIMMOX-2

Phase 2 Active not recruiting

80 enrolled

Adenocarcinoma, Mucinous, Carcinoma, Signet Ring Cell

NCT03108131 2025-05-28

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Phase 2 Completed

49 enrolled 10 charts

Adenocarcinoma, Mucinous, Neoplasm Metastasis, Neoplasms

NCT01037049 2018-09-17

Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks

Phase 2 Unknown

237 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Adenocarcinoma, Mucinous, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms, Neoplasms, Cystic, Mucinous, and Serous

Clinical Trials

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

METIMMOX-2

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks